Annals of Oncology Advance Access originally published online on October 31, 2007
Annals of Oncology 2008 19(4):623-629; doi:10.1093/annonc/mdm500
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
reviews |
Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop
1 Sydney Cancer Centre, Concord Repatriation General Hospital, Cancer Institute, New South Wales, Australia
2 Department of Neuro-Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX
3 Department of Psychiatry and Behavioural Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
4 Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
5 Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
* Correspondence to: Dr S. B. Schagen, Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel: +31-20-5122480; Fax: +31-20-5122322; E-mail: s.schagen{at}nki.nl
A subset of survivors has cognitive impairment after cancer treatment. This is generally subtle, but may be sustained. In October 2006, the second international cognitive workshop was held in Venice. The workshop included neuropsychologists, clinical and experimental psychologists, medical oncologists, imaging experts, and patient advocates. The main developments since the first Cognitive Workshop in 2003 have been the following. (i) studies evaluating cognitive function in patients receiving chemotherapy for cancers other than breast cancer, and in patients receiving hormonal therapy for cancer. (ii) The publication of longitudinal prospective studies which have shown that some patients already exhibit cognitive impairment on neuropsychological testing before receiving chemotherapy, and some patients have deterioration in cognitive functioning from pre- to postchemotherapy. (iii) Studies of the underlying mechanisms of cognitive impairment both in patients and in animal models. (iv) Use of structural and functional imaging techniques to study changes in brain morphology and activation patterns associated with chemotherapy. (v) At present cognitive research in cancer is limited by methodological challenges and the lack of standardization in neuropsychological studies. The current workshop addressed many of these issues and established an international task force to provide guidelines for future research and information on how best to manage these symptoms.
Key words: chemotherapy, cognition, neurotoxicity, side-effects, systemic therapy
Received for publication September 3, 2007. Accepted for publication September 27, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. A. Castellon and P. A. Ganz Exploring the Impact of the Hormonal Milieu on Cognitive Functioning J. Clin. Oncol., November 1, 2009; 27(31): 5119 - 5121. [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Kadan-Lottick, P. Brouwers, D. Breiger, T. Kaleita, J. Dziura, H. Liu, L. Chen, M. Nicoletti, L. Stork, B. Bostrom, et al. A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia Blood, August 27, 2009; 114(9): 1746 - 1752. [Abstract] [Full Text] [PDF]
|
|